| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-N-amido-PEG2-acid does not have a biological target; it is a chemical linker for bioconjugation. The Fmoc group protects the amine during synthesis and can be removed under basic conditions. The terminal carboxylic acid enables coupling to amine-containing molecules, while the PEG spacer improves solubility and reduces aggregation.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system.
In vitro activity is not applicable as this is a chemical linker, not a bioactive compound. Its utility lies in its chemical reactivity rather than biological activity. The compound is used in solid-phase peptide synthesis (SPPS) and the synthesis of antibody-drug conjugates (ADCs) and PROTACs. |
| ln Vivo |
In vivo activity is not applicable as this is a chemical linker used for in vitro synthesis and conjugation. The compound is not a therapeutic agent and is not administered to animals for pharmacological effects. Its applications are in the chemical synthesis of bioconjugates and drug delivery systems.
|
| Enzyme Assay |
For non-cellular assays, Fmoc-N-amido-PEG2-acid is used in chemical conjugation reactions. The carboxylic acid group can be activated with coupling reagents (e.g., HATU, EDC) to form amide bonds with amine-containing molecules. The Fmoc group can be deprotected with piperidine to reveal a free amine for further conjugation. Reaction progress is monitored by TLC, HPLC, or mass spectrometry.
|
| Cell Assay |
In vitro cellular assays are not applicable as this compound is a chemical linker used in synthesis, not a bioactive molecule. It may be used to synthesize conjugates that are later tested in cellular assays, but the linker itself does not have direct cellular activity. Its role is to provide a hydrophilic PEG spacer and orthogonal functional groups for bioconjugation.
|
| Animal Protocol |
In vivo animal experiments are not applicable as this compound is a chemical linker, not a therapeutic agent. It is used in the synthesis of conjugates that may be tested in animal models, but the linker itself is not administered to animals. Its properties contribute to the pharmacokinetic and biodistribution profile of the final conjugate.
|
| ADME/Pharmacokinetics |
Fmoc-N-amido-PEG2-acid has a molecular weight of 399.44 and a molecular formula of C₂₂H₂₅NO₆. It is a solid at room temperature and is typically stored at -20°C. The compound is soluble in organic solvents such as DMSO and DMF. The PEG2 spacer provides moderate hydrophilicity and flexibility to conjugated molecules.
|
| Toxicity/Toxicokinetics |
Fmoc-N-amido-PEG2-acid is a chemical reagent and is not intended for therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. It may cause skin irritation (H315), serious eye irritation (H319), and respiratory irritation (H335). Appropriate personal protective equipment should be used.
|
| References | |
| Additional Infomation |
Fmoc-N-amido-PEG2-acid is a PEG linker used in peptide synthesis, ADC development, and PROTAC synthesis. The Fmoc group provides orthogonal protection for the amine, enabling stepwise synthesis. The short PEG2 spacer improves solubility and reduces aggregation in bioconjugates. The compound is available from various commercial suppliers for research applications.
|
| Molecular Formula |
C22H25NO6
|
|---|---|
| Molecular Weight |
399.4370
|
| Exact Mass |
399.168
|
| CAS # |
872679-70-4
|
| PubChem CID |
51340973
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
622.1±55.0 °C at 760 mmHg
|
| Flash Point |
330.0±31.5 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.584
|
| LogP |
2.96
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
29
|
| Complexity |
505
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NCCOCCOCCC(=O)O
|
| InChi Key |
QWHLFJJLRVOHTM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H25NO6/c24-21(25)9-11-27-13-14-28-12-10-23-22(26)29-15-20-18-7-3-1-5-16(18)17-6-2-4-8-19(17)20/h1-8,20H,9-15H2,(H,23,26)(H,24,25)
|
| Chemical Name |
3-[2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5035 mL | 12.5175 mL | 25.0350 mL | |
| 5 mM | 0.5007 mL | 2.5035 mL | 5.0070 mL | |
| 10 mM | 0.2504 mL | 1.2518 mL | 2.5035 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
